Shopping Cart
- Remove All
- Your shopping cart is currently empty
Nordihydroguaiaretic acid (NDGA) is a natural product, extracted from Pole Fork Kelaroa, and is a lipoxygenase (5-LOX) inhibitor (IC50=8 μM). Nordihydroguaiaretic acid possesses antioxidant and free radical scavenging properties.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 mg | $33 | In Stock | |
100 mg | $45 | In Stock | |
500 mg | $133 | In Stock | |
1 mL x 10 mM (in DMSO) | $52 | In Stock |
Description | Nordihydroguaiaretic acid (NDGA) is a natural product, extracted from Pole Fork Kelaroa, and is a lipoxygenase (5-LOX) inhibitor (IC50=8 μM). Nordihydroguaiaretic acid possesses antioxidant and free radical scavenging properties. |
Targets&IC50 | 5-LOX:8±3 μM |
In vitro | METHODS: Voxelotor (3-30 µmol/L) was incubated with hemoglobin (25 µmol/L) in TES or saline buffer at 37 ℃ for 45 min, and changes in the binding affinity of O2 for Hb were measured using a TCS hematology analyzer. RESULTS: Voxelotor, a small molecule that binds to the N-terminal α-chain of Hb, increases the affinity of HbS for oxygen, delays HbS polymerization in vitro and prevents erythrocyte sickling. [1] METHODS: HepG2 cells were treated with Voxelotor (1 µg/mL) and their metabolites were analyzed by liquid chromatography, high resolution MS and tandem MS. RESULTS: Voxelotor can be used for the identification of phase I and phase II metabolites in vitro. [2] |
In vivo | METHODS: To assess the activity and efficacy of Voxelotor, Voxelotor (100-150 mg/kg, 0.5% methylcellulose/0.5% SDS) was administered by gavage to a mouse model of SCD twice daily for 9-12 days. RESULTS: Voxelotor reduced isolated sickle cells and prolonged erythrocyte half-life in the SCD mouse model. [1] |
Alias | NDGA, Dihydronorguaiaretic Acid |
Molecular Weight | 302.36 |
Formula | C18H22O4 |
Cas No. | 500-38-9 |
Smiles | CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1 |
Relative Density. | 1.0772 g/cm3 (Estimated) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 43 mg/mL (142.21 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+90% Saline: 4.3 mg/mL (14.22 mM), In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.